Among the growing list of ion channels expressed in normal and tumor prostate epithelial cells, Transient Receptor Potential Melastatin 8 (TRPM8) stands out as one of the most promising clinical targets for PCa treatment [10–12]. Here, TRPM8 is linked to posterior cortical atrophy.